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Glucose-6-phosphate dehydrogenase (G6PD) is a highly polymorphic enzyme that is encoded by human X-
linked gene.G6PD deficiency is the most common enzymopathy in human with approximately 400 million 
people affected worldwide. According to the previous studies, Mediterranean mutation (C563T) is one of the 
most common G6PD enzyme mutations in Iranian population with a prevalence range of %63 to %86/4.This 
study was conducted in order to determine Mediterranean mutation, through molecular method ,in the 
population of the North-west of Iran. In this study, by Rapid Genomic DNA Extraction (RGDE) method, from 
77 blood samples of unrelated male and female patients with genetic deficiency of G6PD, DNA was extracted 
and after digestion by MboII enzymes, in order to search for Mediterranean mutation, they were analyzed by 
means of PCR-RFLP and sequencing methods. Of the 77 patients, 48 patients (37 male, 11 female) had a 
Mediterranean mutation frequency of 62/3 %. 29 patients (37/7%) had mutations other than Mediterranean type. 
This study revealed that G6PD is the most common mutation in Iranian North-west population. Further studies 
are recommended to identify the mutation type of other varieties.   
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Introduction 
The enzyme G6PD (Glucose-6-phosphate 
Dehydrogenase) is one of the most important 
enzymes in human body, which different cells in 
human body including red blood cells contain 
varying amounts of the enzyme (Vulliamy et al., 
1992). G6PD catalyzes the first and pace-making 
reaction of the pentose phosphate cycle (PPC) by 
which glucose6-phosphate (G6P) is oxidized to 6-
phosphogluconolactone with production of NADPH 
(Grimes,1980; Beutler, 2001; Cappellini et al., 
2008; Arese et al., 1990). PPC converts glucose into 
pentose phosphates and produces reducing power in 
the form of NADPH. In RBCs NADPH is essential 
for the protection against oxidative stress (Pandolfi 
et al., 1995). A major role of NADPH is to maintain 
reduced glutathione (GSH) at a ratio greater than 
500:1 over the oxidized form GSSG (Cappellini et 
al., 2008; Arese et al., 1990). GSH plays a vital role 
in antioxidant defense by reacting with H2O2 and 
organic peroxides as well as by maintaining thiol 
groups of Hb, other proteins and enzymes in the 
reduced state. H2O2 can be also detoxified by 
catalase which is also stabilized by tightly bound 
NADPH (Gaetani et al., 1996; Scott et al., 1993). 
The major clinical manifestations of G6PD 
deficiency are Acute Hemolytic Anemia, Neonatal 
Jaundice, Mental Retardation, Chronic Renal 
Failure, Chronic nonspherocytic Hemolytic 
Anemia. in children or adults with G6PD deficiency 
using of some substances such as Anti-
malarialdrugs, oxidizing materials, or fava beans 
(Vicia faba) causes severe hemolytic attacks which 
can be life-threatening (Beutler et al., 1994; Malluh 
et al., 1992). 
The gene encoding G6PD is located on the long 
arm of the X chromosome (Xq28) and consists of 
13 exons and 12 introns, spanning approximately 18 
kb. The coding sequencing of the gene is 1,545 bp 
long, coding for the 515 amino acids of the G6PD 
primary sequence (Arese et al., 2012). 
Due to the location of genes, heredity of G6PD 
is a X-linked pattern (Mortazavi et al., 2006). 
Hence, the defective gene in men is fully out 
broken. In females due to having two X 
chromosomes, different forms of homozygote and 
heterozygote are visible (Beutler, 1994). 
Glucose-6-phosphate dehydrogenase enzyme 
deﬁciency is one of the most frequent human 
genetic disorders so that more than 400 million 
people are aﬀected worldwide (Ruwende et al., 
1995). However; its prevalence in different 
populations varies from 1 to 65% (Mason et al., 
2007). 
Although Iranian population consists of 
different ethnic groups, but the overall incidence of 
G6PD deficiency in Iranian population is estimated 
around 10%-14.9% (Noori-Daloii et al., 2007). 
Some studies were carried out on the molecular 
basis of G6PD deficiency in Iran and showed that 
the Mediterranean mutation have the highest 
frequency in Gilan, Mazandaran, Golestan (Noori-
Daloii et al., 2006b). Khorasan, Hormozgan, 
Sistan&Baluchestan, Yazd and Kerman (Noori-
Daloii et al., 2007). 
In most cases displacement of a base at the 
DNA level, causes the displacement of one amino 
acid with another amino acid. Normal typeG6PD is 
known type B. About 20 percent of black African 
have G6PDtype (A +) which is normal in terms of 
activity but is different with type B in terms of one 
amino acid and can be identified by electrophoresis 
(Luzzatto, 1973). Some African descents with 
G6PDtype (A-)  have unstable G6PD because of 
mutations in the DNA. 
Type Mediterranean G6PDis the most common 
type of G6PD and its symptoms are more severe 
than of type (A-). This variant can be found in the 
Mediterranean regions (Italy, Greece, Sardinia), the 
Jewish Kurds and Arabs, India and in Southeast of 
Asia (Luzzatto, 1973; Oppenheim et al., 1993). 
 According to previous studies, the most 
prevalent mutations in Iran are Mediterranean, 
Chatham and Cosenza. The purpose of this study is 
to investigate the frequency rate of the 
Mediterranean mutation in north-west of Iran. 
Materials and Methods 
In this cross-sectional study, 77 Peripheral 
blood samples (2-5 ml in 300 μ EDTA 0.5 M) from 
unrelated patients with G6PD deficiency were 
collected from the hospitals of the north-west of 
Iran (including Ardebil, Tabriz and Urmia 
provinces). The blood samples collection process 
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was performed with the ethics committee approval 
and the patients’ informed consent through 
telephone correspondences. and until the DNA 
extraction, the falcons were held in the temperature 
of -20
o
C.Qualitative measurement of the enzyme 
activity was performed using Fluorescent Spot Test 
and Saba laboratory kit. The basis of this method is 
the catalytic activity of G6PDenzyme in conversion 
of G6PD Glucose 6-phosphate to 6-
Phosphogloconate and simultaneous revival of 
NADP to NADPH2. The produced NADPH2 has 
fluorescent specifications under UV (365nm). The 
fluorescence intensity in the blood of healthy 
individuals is positive (strong) and in the blood of 
patients with G6PD deficiency is low or 
negative.Extraction and purification of the samples’ 
DNA Genomic, from Peripheral blood leukocytes, 
was performed by Rapid Genomic DNA Extraction 
(RGDE) method. 
RGDE method was performed as follow 
(Saremi et al., 2010): 
Pouring 500  or 0.5 gr of blood sample into a 
1.5 ml microfuge tube and 1000  of Cell Lysis 
buffer. 
Shaking microfuge tube gently, and then 
centrifuging it for 2 minutes at 6000 rpm.  
Removing and discarding supernatant and 
repeating steps 1-3 two or three.  
Adding 300  of Nuclei Lysis buffer to the 
microfuge tube and keeping the tube in room 
temperature for 2 minutes to prevent clot formation. 
Adding 100  of saturated NaCl and 600  of 
Chloroform to the microfuge tube, shaking it gently 
then centrifuging it for 2 minutes at 6000 rpm.  
Transferring 300-400  of supernatant to a 
new 1.5ml microfuge tube.  
Adding 600 of cold Isopropanol to it; shaking 
it gently then quickly. 
Centrifuging the microfuge tube for one minute 
at 13000 rpm to precipitate, and then removing 
some of supernatant and letting completely dried in 
room temperature and keeping it for later uses. 
Amplification of exon 6 from the G6PD gene 
was performed by primers F-Med [5'CCC CGA 
AGA GGA ATT CAA GGG GGT 3'] and R-Med 
[5'GAA GAG TAG CCC TCG AGG GTG ACT 3'] 
92 in thermal cycler (Senso Quest-Germany) .For 
each subject patient, 3μl of the mentioned primers, 
DFS-Taqmaster mix 12/5 μl (Bioron-Germany) was 
added to the PCR tube. Then 2μl of the DNA was 
added to the tube and until the tube’s final volume 
25μl distilled water (dH2O) was added to it.PCR 
conditions were as follows: Initial denaturation of 
DNA at 95 ˚C for 5 min. 35 cycles each consisting 
of three steps of denaturation at 94 ˚C for 1 min, 
annealing at 59 ˚C for 1 min, extension at 72 ˚C for 
1 minute and final extension at 72˚C for 5 minutes. 
PCR Products were electrophoresed on 1.5% 
agarose gel at presence of DNA Ladder 50-700 bp 
(Bioron-Germany) and negative control samples. 
(fig. 1)Then583bp fragment, the amplified product, 
was digested by enzymes MboII. 
For digestion of 10μl PCR products, 2μl of 10X 
Enzyme buffer (B
+) and 1μl MboII Enzyme 
(Fermentas Co.) were mixed in a tube and until the 
tube’s final volume, 31μl dH2O was added to it. 
The Mixture was transferred to the Thermal Cycler 
device and for each of the cycle, the temperature of 
65˚C for 2 hours and the temperature of37˚C for 25 
minutes were adjusted and digested products were 
electrophoresed on 1.5-2% agarose gel at presence 
of DNA Ladder and negative control samples. In 
case of the absence of Mediterranean mutation and 
the enzymatic digestion, 379 bp, 120 bp, 60 bp, 24 
bp bands are visible. If there is a mutation, 379bp 
band is cut and turns to 276bp and 103 bp. (fig. 2). 
To study the G6PD genetic changes (exon 6) 
accurately, DNA Sequencing was performed in a 
randomly selected sample of Mediterranean Mutant. 
To do so the PCR product was sent to Fazapazhouh 
Company (USA) and the response was analyzed by 
means of Chromas Lite version 2.33 software (fig. 
3). 
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Fig. 1: The results of amplification of nucleotide sequence containing Mediterranean mutation. 
Lanes1-20: PCR product. Lane 10: negative control. L:50 bp plus DNA Ladder. 
 
 
Fig. 2: Restriction digestion analysis of PCR products related to G6PD Mediterranean mutation 
withMboII.Lanes:1,4,8,10,11,16:normalsamples.Lane 2: G6PD-Med Positive 




The results of DNA Sequencing for a sample of patient with 563 mutation (C-T) (top) and healthy individual 
(bottom). 
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As it was shown in the rectangular, in the patient sample C base has been replaced with T base. 
 
(TCC 188 TTC)            (Ser 188 Phe) 
 
Results 
This study was conducted on 77 individuals 
with deficient G6PD enzyme activity. Individuals’ 
ages ranged from one month to 21 years.G6PD 
Mediterranean mutation (563 C-T) was observed in 
48 (37 males and 9 females) cases, which represents 
the prevalence rate of 62/3%. 29 patients (37/7%) 
weren’t affected by the Mediterranean-type 
mutation. Mediterranean defect prevalence rate was 
77/1% in men and 22/9% in womenand it shows the 
high incidence of this disease in males and X-
Linked recessive pattern of inheritance. Among 
women, 9 cases (81/8%) were heterozygote females 
and 3 cases (18/2%) were homozygote. 
Discussion 
Using RFLP-PCR, this study showed 
that62/3% of individuals with Mediterranean type 
enzyme deficiency has mutations in nucleotide 563 
(C-T) of G6PD gene. In these individuals, at 
position 188, phenylalanine amino acid is replaced 
by serine. G6PD is one of the most common genetic 
diseases that many people in the world suffer from 
it. This disease has caused many damages on child 
development and it has taken into consideration by 
the World Health Organization.On the basis of 
different studies, Mediterranean mutation 
prevalence is different around the world and 
Iran.G6PD Mediterranean mutation prevalence is 
79% in turkey (Keskin et al., 2002), 80% in Saudi 
Arabia (Niazi et al., 1996), 74% in Oman (Darr et 
al., 1996), 55% in UAE (Bayoumi et al., 1996), and 
76% in Pakistan (Saha et al., 1994). Noori-Daloii et 
al., studies conducted in northern, central and 
southern provinces of Iran (table 1) (Noori-Daloii et 
al., 207, 2006b), showed that the lowest and the 
highest prevalence of Mediterranean mutation in 
patients withG6PD deficiency belongs to Kerman 
63% and Gilan 86.5% provinces, respectively.  
 
Table 1: Prevalence of Mediterranean mutation in north,center and south of Iran. 
 Area
‚
s group  
Northern provinces Central provinces Southern provinces 
Gilan 86.4 % Yazd 64 % Sistan and Baluchestan 80% 
Mazandaran 66.2 % Kerman 63% Hormozgan 79% 
Golestan 69 %   
Khorasan 66%   
  
 
The Studies of Karimi et al., in Fars Province 
(Karimni t al., 2003), Miri Moghaddam et al., in 
Sistan and Baluchistan province (Mirimoghaddam 
et al., 2002) and Mortazavi et al., in Zanjan 
province (Mortazavi et al., 2006) have reported 
83.8%, 85.1% and 72.7%, respectively, prevalence 
in these provinces.the present study, prevalence rate 
of the mutation is 62.3% which, compared to the 
reported mutations, represents the lowest prevalence 
rate. This study and the previous studies, conducted 
in the provinces, reveal thatMediterraneanmutation 
type is the dominant mutation in these areas it 
means that inIran, G6PD dominant mutation is 
Mediterranean type. That this mutation has 
happened thousands of years ago and the mutant 
genes have been transferred to other territories 
through migration or population displacement due 
to war and etc. 
Several studies have shown that patients with 
G6PD deficiencyareresistant against catching 
malaria (Guido et al., 2007). Because the 
prevalence rate of Malaria in the northwest of the 
country is lower than the South and Southeast 
regions, so the prevalence of deficiency for this 
region is justifiable. 
Although, due to the inheritance of X-linked 
recessive, it is expected that this deficiency should 
be observed only in males but based on the Lyon’s 
hypothesis (random inactivation of sex 
chromosomes), although less prevalent, it is likely 
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to occur in females. In the present study, like other 
studies, a significant percentage of females (23%) 
had this deficiency. 
29 patients (37.7%) of the subjects had no 
mutations. since more than 60 different mutations 
have been identified at the molecular level 
(Mortazavi et al., 2006). So identification of 
mutations in these patients needs further molecular 
studies and it can be done through using SSCP and 
ARMS-PCR methods andsequencingthe G6PD 
gene. 
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